JP Morgan Chase
AQST icon

JP Morgan Chase’s Aquestive Therapeutics AQST Stock Holding History

JP Morgan Chase’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-350,000
Closed -$1.74M – 7378
2024
Q3 		$1.74M Buy
+350,000
New +$1.36M ﹤0.01% 4105

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JP Morgan Chase's AQST Position: Q1 2026 in Review

JP Morgan Chase reduced its Aquestive Therapeutics (AQST) stake by 83% in Q1 2026, selling an estimated $1.28M and leaving 64,438 shares worth $260K. The position accounts for ﹤0.01% of the portfolio, ranked #5340.

JP Morgan Chase first reported a position in AQST in Q3 2018 and has held it in 31 quarters since. The position peaked at $2.65M in Q3 2025. 179 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

  • JP Morgan Chase held 64,438 shares of Aquestive Therapeutics worth $260K as of Q1 2026.
  • JP Morgan Chase sold 314,979 Aquestive Therapeutics shares in Q1 2026, an estimated $1.28M.
  • Aquestive Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #5340 holding.
  • JP Morgan Chase first reported a position in Aquestive Therapeutics in Q3 2018 and has held it in 31 quarters since.
  • JP Morgan Chase's Aquestive Therapeutics position peaked at $2.65M in Q3 2025.
  • 179 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.